.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Superseded assessment report on Urtica dioica L., Urtica urens L., their hybrids...
Minutes - PDCO minutes of the 28-31 January 2025 meeting
Management Board meeting: 13 March 2025, European Medicines Agency, Amsterdam, t...
Agenda - Management Board meeting: 13 March 2025
Clinical investigation of medicinal products in the treatment of depression - Sc...
Clinical investigation of medicinal products in the treatment of epileptic disor...
Minutes of the PRAC meeting 13-16 January 2025
European Medicines Agency's data protection notice on the use of SNDS data for t...
Data Protection Notice on the use of SNDS data for the performance of DARWIN EU®...
Human medicines European public assessment report (EPAR): Vocabria, cabotegravir...
Quarterly System Demo - Q1 2025, Online, European Medicines Agency, Amsterdam, t...
Release notes - production release version 1.7.2514 - 12 March 2025 - Veterinary...
Human medicines European public assessment report (EPAR): Rytelo, imetelstat, Da...
Human medicines European public assessment report (EPAR): Paxneury, guanfacine, ...
Human medicines European public assessment report (EPAR): Andembry, garadacimab,...
Human medicines European public assessment report (EPAR): mResvia, Single-strand...
Human medicines European public assessment report (EPAR): Rybrevant, amivantamab...
Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, ...
Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, ...
SPOR and XEVMPD status update webinar, Broadcast, from 8 October 2025, 10:00 (CE...
Recommendations on eligibility to PRIME scheme - Adopted at the CHMP meeting 24-...
Orphan designation: Venetoclax Treatment of mantle cell lymphoma, 12/12/2017 Wit...
Orphan designation: Venetoclax Treatment of diffuse large B-cell lymphoma, 14/10...